About 95% of rare disorders don’t have a treatment for it, and even in cases where treatment is available or a clinical trial is being conducted, not everyone across the world has equal access to it. That’s what’s happening now in the context of Duchenne Muscular Dystrophy. Here to help us dive into this and why equitable access to treatments matter, we speak to Catherine Jayasuriya, Founder & Executive Director, Coalition Duchenne, and Nadiah Hanim Abdul Latif, President, Malaysia Rare Disorders Society.

Image Credit: Catherine Jayasuriya